V. Tolmachev

S. Hober, V. Tolmachev, A. Orlova, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

V. Tolmachev, A. Orlova, A. Vorobyeva, 2021, The Journal of Nuclear Medicine.

Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake

P. Jonasson, J. Feldwisch, V. Tolmachev, 2021, International journal of molecular sciences.

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors

V. Tolmachev, A. Orlova, Mohamed Altai, 2018, Contrast media & molecular imaging.

Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

L. Abrahmsén, J. Feldwisch, V. Tolmachev, 2010, Journal of Nuclear Medicine.

Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.

H. Lundqvist, V. Tolmachev, M. Sandström, 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells

H. Lundqvist, J. Carlsson, V. Tolmachev, 2001 .

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.

S. Ståhl, J. Löfblom, V. Tolmachev, 2014, European journal of medicinal chemistry.

Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma

J. Nilvebrant, V. Tolmachev, O. Eriksson, 2015, International journal of oncology.

Abstracts of the 33rd International Austrian Winter Symposium

M. Knopp, J. Karp, M. Schwaiger, 2018, EJNMMI Research.

Evaluation of Cysteine-Based Chelators for Attachment of 99 mTc to Tumor-Targeting Affibody Molecules

A. Bruskin, A. Karlström, V. Tolmachev, 2022 .

Research Highlights: Highlights from the latest articles on bombesin-based radiopeptides for prostate cancer diagnostics

V. Tolmachev, A. Orlova, 2012 .

Spacer as a biodistribution modifier for 99 mTc-labeled bombesin

V. Tolmachev, A. Orlova, 2012 .

Efficient Synthesis of ω‐[ 18 F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission Tomography

V. Tolmachev, M. Yusubov, V. Zhdankin, 2020 .

Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives.

V. Tolmachev, E. Mume, S. Sjöberg, 2005, Carbohydrate research.

Optimization of Iodination of [125I]-N-Succinimidyl-Para-Iodobenzoate Using Chloramine-T for Labeling of Proteins

H. Lundqvist, V. Tolmachev, A. Orlova, 2000 .

Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent

A. Sundin, V. Tolmachev, A. Orlova, 2002 .

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26

V. Tolmachev, A. Orlova, Mohamed Altai, 2019, International journal of cancer.

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551

L. Abrahmsén, V. Tolmachev, A. Orlova, 2012, The Journal of Nuclear Medicine.

Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solution using Chloramine-T

A. Bruskin, H. Lundqvist, V. Tolmachev, 2002 .

Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).

A. Bruskin, H. Lundqvist, J. Carlsson, 2004, Nuclear medicine and biology.

Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.

V. Tolmachev, S. Ahlgren, K. Andersson, 2010, Nuclear medicine and biology.

Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI).

A. Bruskin, H. Lundqvist, V. Tolmachev, 2006, Anticancer research.

Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides.

H. Lundqvist, V. Tolmachev, A. Orlova, 2003, Current medicinal chemistry.

Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.

P. Malmström, V. Tolmachev, A. Orlova, 2007, International journal of molecular medicine.

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

T. Tötterman, V. Tolmachev, A. Orlova, 2013, Cancer Immunology Research.

Disseminated Bladder Cancer Secondary Lymphoid Organs and Eradicates Experimental Locally Delivered CD 40 Agonist Antibody Accumulates in

V. Tolmachev, A. Orlova, P. Ellmark, 2013 .

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

A. Karlström, V. Tolmachev, A. Orlova, 2018, The Journal of Nuclear Medicine.

Radionuclide molecular imaging using Affibody molecules.

V. Tolmachev, S. Ahlgren, 2010, Current pharmaceutical biotechnology.

Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

V. Tolmachev, A. Orlova, Mohamed Altai, 2014, Amino Acids.

Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab.

S. Hosseinimehr, V. Tolmachev, A. Orlova, 2010, Human antibodies.

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

A. Schulga, V. Tolmachev, S. Deyev, 2022, Oncology reports.

PRODUCTION OF 76BR BY A LOW-ENERGY CYCLOTRON

H. Lundqvist, V. Tolmachev, A. Lövqvist, 1998 .

High yield [125 I]Iodide-Labeling of Iodinated Carboranes By Palldium-Catalyzed Isotopic Exchange

V. Tolmachev, F. Teixidor, C. Viňas, 2003 .

Labelling and in vivo evaluation of closo-dodecaborate as a linker for attachment of iodine to radiopharma-ceuticals

H. Lundqvist, J. Carlsson, A. Sundin, 1997 .

Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media

V. Tolmachev, A. Orlova, E. Shchukin, 2004 .

Bromination of closo‐dodecaborate (2‐) anion in aqueous media using chloramine‐T

H. Lundqvist, V. Tolmachev, S. Sjöberg, 2001 .

[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation.

V. Tolmachev, A. Orlova, M. Babaei, 2005, Oncology reports.

A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers

D. Gorin, G. Sukhorukov, B. Parakhonskiy, 2021, Applied Materials Today.

The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule

J. Löfblom, V. Tolmachev, A. Orlova, 2021, Pharmaceutics.

Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy

H. Lundqvist, V. Tolmachev, E. Mume, 2005 .

Feasibility of isotopic exchange in the system [125I] iodide - undecahydro-iodo-closo-dodecaborate(2-) anion

V. Tolmachev, A. Orlova, E. Shchukin, 2003 .

Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

J. Feldwisch, V. Tolmachev, A. Orlova, 2011, Nuclear medicine and biology.

Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.

V. Tolmachev, A. Orlova, Jennie Malmberg, 2011, International journal of oncology.

Design of an optimized scaffold for affibody molecules.

Joachim Feldwisch, Vladimir Tolmachev, Anna Sjöberg, 2010, Journal of molecular biology.

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

A. Schulga, V. Tolmachev, A. Orlova, 2021, Cancers.

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts

V. Tolmachev, A. Orlova, Mohamed Altai, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.

K. Wester, V. Tolmachev, A. Orlova, 2011, Nuclear medicine and biology.

Novel approach to radionuclide therapy of cancer: affibody-based bio-orthogonal chemistry mediated pretargeting

V. Tolmachev, D. Dobritzsch, 2015 .

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

A. Schulga, J. Löfblom, V. Tolmachev, 2019, Molecular pharmaceutics.

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.

Vladimir Tolmachev, Hans Lundqvist, Mattias Sandström, 2007, Cancer research.

Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

K. Wester, H. Lundqvist, M. Nistér, 2006, Journal of neuro-oncology.

Production of 61Cu from a natural nickel target.

H. Lundqvist, V. Tolmachev, L. Einarsson, 1998, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

A. Schulga, V. Tolmachev, A. Orlova, 2023, International journal of molecular sciences.

Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.

A. Bruskin, J. Carlsson, V. Tolmachev, 2004, Cancer biotherapy & radiopharmaceuticals.

Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.

E. Johansson, I. Höidén-Guthenberg, S. Ståhl, 2008, Journal of molecular biology.

Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 Affibody molecule

Fredrik Y Frejd, I. Höidén-Guthenberg, E. Gunneriusson, 2014, International journal of oncology.

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

C. Ekblad, V. Tolmachev, F. Frejd, 2022, Pharmaceutics.

[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

H. Lundqvist, H. Nordgren, J. Carlsson, 2007, Cancer research.

Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.

A. Karlström, V. Tolmachev, A. Orlova, 2012, Bioconjugate chemistry.

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution

V. Tolmachev, A. Orlova, T. Gräslund, 2021, Pharmaceutics.

Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

S. Stone-Elander, V. Tolmachev, A. Orlova, 2010, The Lancet. Oncology.

99mTc-1-Thio-D-Glucose in Lymphoma Patients: Safety, Pharmacokinetics and Dosimetric Characteristics

V. Tolmachev, O. Bragina, V. Chernov, 2022, Journal of oncology: diagnostic radiology and radiotherapy.

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

V. Tolmachev, A. Orlova, T. Gräslund, 2020, Cancers.

Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice

G. Adams, J. Carlsson, S. Ståhl, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF

E. Blomquist, J. Carlsson, V. Tolmachev, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

125I-labeled quercetin as a novel DNA-targeted radiotracer.

B. Stenerlöw, S. Hosseinimehr, V. Tolmachev, 2011, Cancer biotherapy & radiopharmaceuticals.

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct

S. Ståhl, J. Löfblom, V. Tolmachev, 2017, Scientific Reports.

Protein interactions with the HER2 receptor can have different characteristics depending on the hosting cell-line

V. Tolmachev, A. Orlova, K. Andersson, 2012 .

Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine

Joachim Feldwisch, Vladimir Tolmachev, L. Dinkelborg, 2009, Journal of Nuclear Medicine.

Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain.

G. Antoni, K. Magnusson, L. Lannfelt, 2013, Journal of Alzheimer's disease : JAD.

Targeting peptides and positron emission tomography.

Vladimir Tolmachev, Hans Lundqvist, H. Lundqvist, 2002, Biopolymers.

In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab.

P. Malmström, V. Tolmachev, L. Gedda, 2007, Cancer biotherapy & radiopharmaceuticals.

Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.

H. Lundqvist, P. Malmström, V. Tolmachev, 2006, Oncology reports.

[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Vladimir Tolmachev, Mattias Sandström, Jörgen Carlsson, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.

A. Bruskin, H. Lundqvist, E. Blomquist, 2003, Cancer biotherapy & radiopharmaceuticals.

Cellular uptake and processing of directly and indirectly 125I-iodinated and 76Br-brominated monoclonal antibody A33

H. Lundqvist, A. Sundin, V. Tolmachev, 2001 .

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules

V. Tolmachev, F. Frejd, A. Orlova, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Differences in radiosensitivity between three HER2 overexpressing cell lines

Vladimir Tolmachev, Jörgen Carlsson, Bo Stenerlöw, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology

V. Tolmachev, A. Orlova, Sara S Rinne, 2021, International journal of molecular sciences.

Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry

S. Ståhl, V. Tolmachev, F. Frejd, 2009, Journal of Nuclear Medicine.

Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.

J. Carlsson, S. Ståhl, V. Tolmachev, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Synthesis and chemoselective intramolecular crosslinking of a HER2‐binding affibody

A. Karlström, L. Abrahmsén, V. Tolmachev, 2009, Biopolymers.

Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe

E. Langella, R. Bianco, V. Tolmachev, 2018, Scientific Reports.

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26

V. Tolmachev, A. Orlova, U. Rosenström, 2019, Scientific Reports.

Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.

V. Tolmachev, M. Anniko, M. Nestor, 2011, Nuclear medicine and biology.

In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.

A. Sundin, V. Tolmachev, C. Divgi, 2006, Nuclear medicine and biology.

A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy Availability of suitable radionuclides

H. Lundqvist, J. Carlsson, V. Tolmachev, 2004, Acta oncologica.

Pharmacokinetics and red cell utilization of iron(III) hydroxide–sucrose complex in anaemic patients: a study using positron emission tomography

M. Lubberink, G. Antoni, B. Långström, 1999, British journal of haematology.

Pharmacokinetics and red cell utilization of 52Fe/59Fe‐labelled iron polymaltose in anaemic patients using positron emission tomography

M. Lubberink, G. Antoni, B. Långström, 2003, British journal of haematology.

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

V. Tolmachev, A. Orlova, Sara S Rinne, 2020, Pharmaceutics.

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.

Fredrik Y Frejd, V. Tolmachev, F. Frejd, 2015, International journal of oncology.

110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.

A. Bruskin, M. Lubberink, H. Lundqvist, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model

V. Tolmachev, A. Orlova, Z. Varasteh, 2020, Pharmaceutics.

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer

V. Tolmachev, A. Orlova, M. Larhed, 2019, Pharmaceutics.

In Vitro and In Vivo Evaluation of a 18F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

G. Antoni, G. Lindeberg, V. Tolmachev, 2013, PloS one.

Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.

A. Karlström, V. Tolmachev, A. Orlova, 2012, Nuclear medicine and biology.

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

S. Ståhl, J. Löfblom, V. Tolmachev, 2021, Cancers.

The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer.

V. Tolmachev, A. Orlova, J. Sörensen, 2021, Seminars in cancer biology.

Site-specific radiometal labeling and improved biodistribution using ABY-027 , a novel HER 2-targeting affibody molecule-ABD fusion protein

H. Lundqvist, C. Ekblad, A. Jonsson, 2014 .

Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein

Fredrik Y Frejd, H. Lundqvist, L. Abrahmsén, 2013, The Journal of Nuclear Medicine.

Disruption of HER2 signalling by the monoclonal antibody trastuzumab or the tyrosine kinase inhibitor lapatinib improves survival of patients with metastatic breast

Vladimir Tolmachev, Mattias Sandström, V. Tolmachev, 2010 .

Update: affibody molecules for molecular imaging and therapy for cancer.

Joachim Feldwisch, Vladimir Tolmachev, L. Abrahmsén, 2007, Cancer biotherapy & radiopharmaceuticals.

Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.

V. Tolmachev, A. Orlova, Torun Engfeldt, 2007, International journal of molecular medicine.

Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.

V. Tolmachev, A. Orlova, M. Sandström, 2007, International journal of molecular medicine.

111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.

Vladimir Tolmachev, Karl Andersson, Lars Gedda, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties.

M. Lubberink, H. Lundqvist, J. Carlsson, 1999, Medical physics.

Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.

S. Ståhl, J. Löfblom, V. Tolmachev, 2017, International journal of oncology.

Correction: Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes

V. Tolmachev, A. Orlova, M. Mazzone, 2015, PloS one.

Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes

S. Tugues, V. Tolmachev, A. Orlova, 2014, PloS one.

Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules

S. Hosseinimehr, S. Ståhl, V. Tolmachev, 2012, Amino Acids.

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

Vladimir Tolmachev, Mattias Sandström, V. Tolmachev, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology

Fredrik Y Frejd, V. Tolmachev, F. Frejd, 2018, The Journal of Nuclear Medicine.

HAHAHA-, HIHIHI-. HKHKHK. HHHHHH- and HEHEHE- tags : Influence of position and composition of histidine-containing tags on biodistribution of [99mTc(CO) 3]+- labeled affibody molecules

S. Hosseinimehr, V. Tolmachev, A. Orlova, 2013 .

[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.

A. Bruskin, E. Blomquist, J. Carlsson, 2004, Cancer biotherapy & radiopharmaceuticals.

Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

I. Höidén-Guthenberg, S. Ståhl, J. Löfblom, 2013, PloS one.

Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line.

V. Tolmachev, A. Orlova, K. Andersson, 2011, International journal of oncology.

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA

Merja Haaparanta-Solin, Vladimir Tolmachev, Johan Rajander, 2017, Contrast media & molecular imaging.

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m

S. Hober, V. Tolmachev, A. Orlova, 2017, Scientific Reports.

HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.

S. Hosseinimehr, V. Tolmachev, A. Orlova, 2013, Journal of medicinal chemistry.

Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design.

S. Hosseinimehr, V. Tolmachev, A. Orlova, 2012, Drug discovery today.

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus

S. Ståhl, V. Tolmachev, A. Orlova, 2012, Tumor Biology.

Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules

S. Hosseinimehr, S. Ståhl, V. Tolmachev, 2011, Amino Acids.

Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

Mathias Uhlén, Vladimir Tolmachev, Stefan Ståhl, 2011, Protein expression and purification.

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

L. Abrahmsén, S. Hosseinimehr, V. Tolmachev, 2010, Bioconjugate chemistry.

Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.

A. Karlström, J. Feldwisch, V. Tolmachev, 2009, Bioorganic & medicinal chemistry letters.

99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule

A. Karlström, L. Abrahmsén, J. Feldwisch, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Fredrik Y Frejd, V. Tolmachev, F. Frejd, 2023, Cancers.

Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

S. Hober, A. Schulga, V. Tolmachev, 2022, International journal of molecular sciences.

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer

A. Schulga, V. Tolmachev, S. Deyev, 2022, International journal of molecular sciences.

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy

A. Karlström, V. Tolmachev, A. Orlova, 2018, Scientific Reports.

Evaluating the therapeutic potential of a dimeric HER 3-binding affibody construct in comparison with a monoclonal antibody , seribantumab MANUSCRIPT

S. Ståhl, V. Tolmachev, F. Frejd, 2017 .

Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

A. Schulga, V. Tolmachev, A. Orlova, 2021, The Journal of Nuclear Medicine.

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3

A. Schulga, J. Löfblom, V. Tolmachev, 2019, Scientific Reports.

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2

J. Löfblom, V. Tolmachev, A. Orlova, 2019, International journal of oncology.

Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition

L. Abrahmsén, V. Tolmachev, A. Orlova, 2012, The Journal of Nuclear Medicine.

Targeted nuclear medicine. Seek and destroy

V. Tolmachev, S. Deyev, V. Chernov, 2022, Russian Chemical Reviews.

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain

P. Jonasson, V. Tolmachev, F. Frejd, 2021, Pharmaceutics.

Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.

S. Hober, V. Tolmachev, A. Orlova, 2020, Biomaterials.

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule

S. Ståhl, J. Löfblom, V. Tolmachev, 2017, Scientific Reports.

Engineering of affibody molecules for therapy and diagnostics.

Joachim Feldwisch, Vladimir Tolmachev, J. Feldwisch, 2012, Methods in molecular biology.

Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer

S. Hober, V. Tolmachev, A. Orlova, 2020, The Journal of Nuclear Medicine.

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.

V. Tolmachev, A. Orlova, Mohamed Altai, 2016, International journal of oncology.

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model

P. Jonasson, S. Ståhl, J. Löfblom, 2020, Pharmaceutics.

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules

S. Ståhl, J. Löfblom, V. Tolmachev, 2020, International journal of molecular sciences.

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs

S. Ståhl, J. Löfblom, V. Tolmachev, 2018, Cells.

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

V. Tolmachev, A. Orlova, U. Rosenström, 2023, Cancers.

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart

V. Tolmachev, A. Orlova, U. Rosenström, 2019, Pharmaceutics.

Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.

Nima Jokilaakso, A. Karlström, V. Tolmachev, 2013, Nuclear medicine and biology.

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

V. Tolmachev, A. Orlova, T. Gräslund, 2022, Pharmaceutics.

Choice of Radionuclides and Radiolabelling Techniques

V. Tolmachev, 2008 .

Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer

Vladimir Tolmachev, Peter Laverman, W. Oyen, 2012, The Journal of Nuclear Medicine.

Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe

E. Langella, R. Bianco, V. Tolmachev, 2018, Scientific Reports.

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors

J. Löfblom, V. Tolmachev, A. Orlova, 2018, Cells.

Affibody-mediated PET imaging of HER3 expression in malignant tumours

S. Ståhl, J. Löfblom, V. Tolmachev, 2015, Scientific Reports.

Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.

S. Ståhl, J. Löfblom, V. Tolmachev, 2015, Oncology reports.

Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule

S. Ståhl, J. Löfblom, V. Tolmachev, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

V. Tolmachev, A. Orlova, K. Andersson, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.

A. Karlström, V. Tolmachev, A. Orlova, 2011, Bioconjugate chemistry.

Kinetic analysis of 52Fe‐labelled iron(III) hydroxide–sucrose complex following bolus administration using positron emission tomography

M. Lubberink, G. Antoni, B. Långström, 1999, British journal of haematology.

Positron emission tomography

M. Lubberink, H. Lundqvist, V. Tolmachev, 1998 .

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount

Vladimir Tolmachev, Mattias Sandström, Anna Sjöberg, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution.

H. Lundqvist, J. Carlsson, A. Sundin, 1999, Bioconjugate chemistry.

Feasibility of palladium-catalyzed isotopic exchange between sodium [125I]I and 2-iodo-para-carborane

V. Tolmachev, S. Sjöberg, Ludvig Eriksson, 2003 .

Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

V. Tolmachev, O. Bragina, V. Chernov, 2022, Bulletin of Siberian Medicine.

Radiobromination of closo‐carboranes using palladium‐catalyzed halogen exchange

V. Tolmachev, E. Mume, S. Sjöberg, 2005 .

Labelling of boron containing compounds with halogen isotopes

H. Lundqvist, V. Tolmachev, A. Orlova, 1997 .

Quantification of CD44v6 and EGFR Expression in Head and Neck Squamous Cell Carcinomas Using a Single-Dose Radioimmunoassay

G. V. van Dongen, K. Wester, V. Tolmachev, 2007, Tumor Biology.

Separation of arsenic from germanium oxide targets by dry distillation

H. Lundqvist, V. Tolmachev, 2014 .

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with 99mTc and 125I

A. Schulga, V. Tolmachev, A. Orlova, 2022, Oncology letters.

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules

S. Ståhl, J. Löfblom, V. Tolmachev, 2020, International journal of molecular sciences.

Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules

S. Ståhl, J. Löfblom, V. Tolmachev, 2019, Scientific Reports.

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers

S. Ståhl, J. Löfblom, V. Tolmachev, 2019, International journal of molecular sciences.

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer

Fredrik Y Frejd, M. Lubberink, H. Lindman, 2020, EJNMMI Research.

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging

A. Schulga, V. Tolmachev, A. Orlova, 2019, International journal of molecular sciences.

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.

V. Tolmachev, A. Orlova, T. Gräslund, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein

S. Hober, V. Tolmachev, A. Orlova, 2021, Pharmaceutics.

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer

V. Tolmachev, A. Orlova, B. Olsen, 2020, Molecules.

Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase.

H. Lundqvist, V. Tolmachev, I. Cotgreave, 1999, The international journal of biochemistry & cell biology.

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

V. Tolmachev, A. Orlova, Mohamed Altai, 2021, Pharmaceutics.

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer

S. Hober, A. Schulga, V. Tolmachev, 2023, Cancers.

In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.

J. Carlsson, S. Ståhl, V. Tolmachev, 2008, Oncology reports.

Synthesis of technetium-chelating affibody molecules for diagnostic imaging of HER2-expressing tumours

J. Feldwisch, V. Tolmachev, A. Orlova, 2006 .

Affibody‐derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over‐expressing tumors

V. Tolmachev, A. Orlova, Mohamed Altai, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity.

S. Ståhl, J. Löfblom, V. Tolmachev, 2023, Journal of Controlled Release.

Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.

G. Lindeberg, V. Tolmachev, A. Orlova, 2016, International journal of oncology.

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1

A. Schulga, V. Tolmachev, A. Orlova, 2020, International journal of molecular sciences.

In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.

H. Lundqvist, A. Sundin, V. Tolmachev, 2005, Cancer Biotherapy and Radiopharmaceuticals.

Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

V. Tolmachev, A. Vorobyeva, O. Bragina, 2021, Bulletin of Siberian Medicine.

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake

S. Ståhl, J. Löfblom, V. Tolmachev, 2019, Scientific Reports.

Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

Fredrik Y Frejd, I. Höidén-Guthenberg, S. Ståhl, 2013, PloS one.

Feasibility of radionuclide imaging of HER3-expressing tumours using technetium-99m labeled affibody molecules

S. Ståhl, J. Löfblom, N. Kronqvist, 2013 .

Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

V. Tolmachev, A. Orlova, J. Sörensen, 2023, Cancers.

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

M. Lubberink, J. Carlsson, H. Lindman, 2014, The Journal of Nuclear Medicine.

V. Tolmachev, A. Orlova, Jennie Malmberg, 2011, Experimental and therapeutic medicine.

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule

V. Tolmachev, A. Orlova, Jennie Malmberg, 2012 .

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551

L. Abrahmsén, V. Tolmachev, A. Orlova, 2012, The Journal of Nuclear Medicine.

66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26

V. Tolmachev, A. Orlova, Sara S Rinne, 2021, Scientific Reports.

Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.

G. Lindeberg, V. Tolmachev, A. Orlova, 2016, International journal of oncology.

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

V. Tolmachev, A. Orlova, P. Kanellopoulos, 2023, Biomolecules.

The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.

G. Lindeberg, V. Tolmachev, A. Orlova, 2015, Nuclear Medicine and Biology.

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

S. Hober, V. Tolmachev, A. Orlova, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods.

S. Stone-Elander, V. Tolmachev, 2010, Biochimica et biophysica acta.

An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay.

H. Lundqvist, B. Stenerlöw, P. Malmström, 2005, International journal of oncology.

In vitro and in vivo Evaluation of the Radiochemical Compound Based on 99mTechnetium Labelled DARPin 9_29 for Molecular Visualization of Malignancies Overexpressing Her2/neu

V. Tolmachev, S. Deyev, A. Vorobyeva, 2020 .

ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.

S. Hober, J. Nilvebrant, Mikael Åstrand, 2015, Cancer research.

Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures

V. Tolmachev, A. Orlova, A. Majouga, 2023, International journal of molecular sciences.

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

V. Tolmachev, A. Orlova, M. Oroujeni, 2023, Frontiers in oncology.